Consun Pharma
Consun Pharma, officially known as China Consun Pharmaceutical Group, is a prominent player in the pharmaceutical industry, headquartered in China (CN). Established in 1995, the company has made significant strides in the development and manufacturing of high-quality pharmaceutical products, primarily focusing on prescription medications and over-the-counter solutions. With a strong operational presence across Asia and expanding into international markets, Consun Pharma is recognised for its commitment to innovation and quality. The company’s core offerings include a diverse range of therapeutic drugs, particularly in the fields of cardiovascular health and anti-infectives, distinguished by their efficacy and safety profiles. Notably, Consun Pharma has achieved several milestones, including certifications from international regulatory bodies, which solidify its market position as a trusted provider in the global pharmaceutical landscape.
DitchCarbon Score
How does Consun Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Consun Pharma's score of 19 is lower than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Consun Pharma's reported carbon emissions
In 2022, Consun Pharma reported total carbon emissions of approximately 72,057,200 kg CO2e, with Scope 1 emissions accounting for about 53,214,680 kg CO2e and Scope 2 emissions at approximately 18,842,520 kg CO2e. The company has not disclosed any Scope 3 emissions data. Comparatively, in 2021, the total emissions were about 71,151,211 kg CO2e, indicating a slight increase in emissions year-on-year. The emissions from Scope 1 and Scope 2 have been consistently reported over the past few years, with Scope 1 emissions in 2021 being approximately 52,549,121 kg CO2e and Scope 2 emissions at about 18,602,090 kg CO2e. Despite these figures, Consun Pharma has not set any specific reduction targets or initiatives as part of their climate commitments, nor have they cascaded any targets from a parent or related organization. The absence of a climate pledge or SBTi targets suggests that the company is currently not engaged in formalised climate action frameworks. Overall, while Consun Pharma has made strides in reporting its emissions, the lack of reduction targets and commitments highlights an area for potential improvement in their sustainability strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Scope 1 | - | 00,000,000 | 00,000,000 | 00,000,000.0 | 00,000,000 |
| Scope 2 | 7,978,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Consun Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
